203 related articles for article (PubMed ID: 31904232)
1. Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist for Use in Central Nervous System Disease Models.
Amaradhi R; Banik A; Mohammed S; Patro V; Rojas A; Wang W; Motati DR; Dingledine R; Ganesh T
J Med Chem; 2020 Feb; 63(3):1032-1050. PubMed ID: 31904232
[TBL] [Abstract][Full Text] [Related]
2. Peripherally Restricted, Highly Potent, Selective, Aqueous-Soluble EP2 Antagonist with Anti-Inflammatory Properties.
Ganesh T; Banik A; Dingledine R; Wang W; Amaradhi R
Mol Pharm; 2018 Dec; 15(12):5809-5817. PubMed ID: 30398879
[TBL] [Abstract][Full Text] [Related]
3. Lead optimization studies of cinnamic amide EP2 antagonists.
Ganesh T; Jiang J; Yang MS; Dingledine R
J Med Chem; 2014 May; 57(10):4173-84. PubMed ID: 24773616
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus.
Rojas A; Ganesh T; Lelutiu N; Gueorguieva P; Dingledine R
Neuropharmacology; 2015 Jun; 93():15-27. PubMed ID: 25656476
[TBL] [Abstract][Full Text] [Related]
5. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2.
Jiang J; Ganesh T; Du Y; Quan Y; Serrano G; Qui M; Speigel I; Rojas A; Lelutiu N; Dingledine R
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3149-54. PubMed ID: 22323596
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the prostaglandin E2 receptor EP2 prevents status epilepticus-induced deficits in the novel object recognition task in rats.
Rojas A; Ganesh T; Manji Z; O'neill T; Dingledine R
Neuropharmacology; 2016 Nov; 110(Pt A):419-430. PubMed ID: 27477533
[TBL] [Abstract][Full Text] [Related]
7. Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury.
Jiang J; Yu Y; Kinjo ER; Du Y; Nguyen HP; Dingledine R
Neuropharmacology; 2019 May; 149():149-160. PubMed ID: 30763657
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.
Ganesh T
Expert Opin Ther Pat; 2015 Jul; 25(7):837-44. PubMed ID: 25772215
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of E-type prostanoid receptors 2 and 4 in microglia stimulated with lipopolysaccharide.
Bonfill-Teixidor E; Otxoa-de-Amezaga A; Font-Nieves M; Sans-Fons MG; Planas AM
J Neuroinflammation; 2017 Jan; 14(1):3. PubMed ID: 28086956
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus.
Jiang J; Yang MS; Quan Y; Gueorguieva P; Ganesh T; Dingledine R
Neurobiol Dis; 2015 Apr; 76():126-136. PubMed ID: 25600211
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological antagonism of EP2 receptor does not modify basal cardiovascular and respiratory function, blood cell counts, and bone morphology in animal models.
Rawat V; Banik A; Amaradhi R; Rojas A; Taval S; Nagy T; Dingledine R; Ganesh T
Biomed Pharmacother; 2022 Mar; 147():112646. PubMed ID: 35091236
[TBL] [Abstract][Full Text] [Related]
12. Development of second generation EP2 antagonists with high selectivity.
Ganesh T; Jiang J; Dingledine R
Eur J Med Chem; 2014 Jul; 82():521-35. PubMed ID: 24937185
[TBL] [Abstract][Full Text] [Related]
13. A rat model of organophosphate-induced status epilepticus and the beneficial effects of EP2 receptor inhibition.
Rojas A; Ganesh T; Wang W; Wang J; Dingledine R
Neurobiol Dis; 2020 Jan; 133():104399. PubMed ID: 30818067
[TBL] [Abstract][Full Text] [Related]
14. Targeting prostaglandin receptor EP2 for adjunctive treatment of status epilepticus.
Nagib MM; Yu Y; Jiang J
Pharmacol Ther; 2020 May; 209():107504. PubMed ID: 32088247
[TBL] [Abstract][Full Text] [Related]
15. Second-Generation Prostaglandin Receptor EP2 Antagonist, TG8-260, with High Potency, Selectivity, Oral Bioavailability, and Anti-Inflammatory Properties.
Amaradhi R; Mohammed S; Banik A; Franklin R; Dingledine R; Ganesh T
ACS Pharmacol Transl Sci; 2022 Feb; 5(2):118-133. PubMed ID: 35187419
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation.
Jiang J; Quan Y; Ganesh T; Pouliot WA; Dudek FE; Dingledine R
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3591-6. PubMed ID: 23401547
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection.
Jiang J; Dingledine R
Trends Pharmacol Sci; 2013 Jul; 34(7):413-23. PubMed ID: 23796953
[TBL] [Abstract][Full Text] [Related]
18. EP2 Receptor Signaling Regulates Microglia Death.
Fu Y; Yang MS; Jiang J; Ganesh T; Joe E; Dingledine R
Mol Pharmacol; 2015 Jul; 88(1):161-70. PubMed ID: 25715797
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer's disease.
Banik A; Amaradhi R; Lee D; Sau M; Wang W; Dingledine R; Ganesh T
J Neuroinflammation; 2021 Nov; 18(1):273. PubMed ID: 34801055
[TBL] [Abstract][Full Text] [Related]
20. EP2-PKA signaling is suppressed by triptolide in lipopolysaccharide-induced microglia activation.
Zhang T; Gong X; Hu G; Wang X
J Neuroinflammation; 2015 Mar; 12():50. PubMed ID: 25880276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
